ES3001126T3 - Derivados de 1-((1H-pirazol-4-il)metil)-3-(fenil)-1,3-dihidro-2H-imidazol-2-ona y compuestos relacionados como antagonistas de GPR139 para el tratamiento de la depresión - Google Patents

Derivados de 1-((1H-pirazol-4-il)metil)-3-(fenil)-1,3-dihidro-2H-imidazol-2-ona y compuestos relacionados como antagonistas de GPR139 para el tratamiento de la depresión Download PDF

Info

Publication number
ES3001126T3
ES3001126T3 ES21737768T ES21737768T ES3001126T3 ES 3001126 T3 ES3001126 T3 ES 3001126T3 ES 21737768 T ES21737768 T ES 21737768T ES 21737768 T ES21737768 T ES 21737768T ES 3001126 T3 ES3001126 T3 ES 3001126T3
Authority
ES
Spain
Prior art keywords
methyl
groups
pyrazol
dihydro
ethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES21737768T
Other languages
English (en)
Spanish (es)
Inventor
Tomoaki Hasui
Satoshi Mikami
Toru Yamashita
Shinji Nakamura
Shinji Morimoto
Toshihiro Imaeda
Kazuaki Takami
Masaki Daini
Hiroyuki Kakei
Minoru Nakamura
Fumie Yamaguchi
Chunxiang Wang
Sachie Takashima
Shogo Hashizume
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ES3001126T3 publication Critical patent/ES3001126T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES21737768T 2020-05-22 2021-05-20 Derivados de 1-((1H-pirazol-4-il)metil)-3-(fenil)-1,3-dihidro-2H-imidazol-2-ona y compuestos relacionados como antagonistas de GPR139 para el tratamiento de la depresión Active ES3001126T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2020090110A JP2021183586A (ja) 2020-05-22 2020-05-22 複素環化合物
PCT/IB2021/000336 WO2021234450A1 (en) 2020-05-22 2021-05-20 1-((1h-pyrazol-4-yl)methyl)-3-(phenyl)-1,3-dihydro-2h-imidazol-2-one derivatives and related compounds as gpr139 antagonists for the treatment of e.g. depression

Publications (1)

Publication Number Publication Date
ES3001126T3 true ES3001126T3 (es) 2025-03-04

Family

ID=76797025

Family Applications (1)

Application Number Title Priority Date Filing Date
ES21737768T Active ES3001126T3 (es) 2020-05-22 2021-05-20 Derivados de 1-((1H-pirazol-4-il)metil)-3-(fenil)-1,3-dihidro-2H-imidazol-2-ona y compuestos relacionados como antagonistas de GPR139 para el tratamiento de la depresión

Country Status (6)

Country Link
US (1) US12630534B2 (enExample)
EP (1) EP4153583B1 (enExample)
JP (3) JP2021183586A (enExample)
AR (1) AR122142A1 (enExample)
ES (1) ES3001126T3 (enExample)
WO (1) WO2021234450A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021183586A (ja) 2020-05-22 2021-12-02 武田薬品工業株式会社 複素環化合物
JP2021183587A (ja) 2020-05-22 2021-12-02 武田薬品工業株式会社 複素環化合物
JP2025510009A (ja) * 2022-02-28 2025-04-14 シロナックス リミテッド. Rip1調節物質、その調製、及び使用
CN117815217B (zh) * 2023-12-29 2026-07-10 郑州大学第三附属医院(河南省妇幼保健院) 一种苯甲酰胺衍生物改善认知功能障碍的用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1194449B1 (en) 1999-06-28 2010-09-22 Oklahoma Medical Research Foundation Inhibitors of memapsin 2 and use thereof
AR052342A1 (es) 2004-12-21 2007-03-14 Janssen Pharmaceutica Nv Derivados sustituidos de triazolona,tetrazolona e imidazolona con actividad selectiva antagonista de alfa2c-adenoreceptores
US8148367B2 (en) 2007-01-12 2012-04-03 Takeda Pharmaceutical Company Limited Renin inhibitors
WO2008094556A2 (en) 2007-01-30 2008-08-07 Biogen Idec Ma Inc. Imidazolone compounds as tgf-beta family type i receptors, alk5 and/or alk4 antagonists
WO2011145735A1 (ja) 2010-05-21 2011-11-24 武田薬品工業株式会社 チアゾール誘導体
JP6779214B2 (ja) * 2015-01-09 2020-11-04 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company Rock阻害剤としての環状ウレア
WO2020097609A1 (en) 2018-11-09 2020-05-14 Blackthorn Therapeutics, Inc. Gpr139 receptor modulators
JP7199940B2 (ja) 2018-12-03 2023-01-06 川崎重工業株式会社 複合材料製航空機用部品およびその製造方法
JP2021183586A (ja) 2020-05-22 2021-12-02 武田薬品工業株式会社 複素環化合物
JP2021183587A (ja) 2020-05-22 2021-12-02 武田薬品工業株式会社 複素環化合物

Also Published As

Publication number Publication date
EP4153583B1 (en) 2024-10-30
AR122142A1 (es) 2022-08-17
JP2025168429A (ja) 2025-11-07
US20230348435A1 (en) 2023-11-02
WO2021234450A1 (en) 2021-11-25
EP4153583A1 (en) 2023-03-29
TW202208349A (zh) 2022-03-01
JP7734152B2 (ja) 2025-09-04
EP4153583C0 (en) 2024-10-30
JP2023528280A (ja) 2023-07-04
JP2021183586A (ja) 2021-12-02
US12630534B2 (en) 2026-05-19

Similar Documents

Publication Publication Date Title
CA3019298C (en) Heterocyclic compound
WO2020122092A1 (ja) 複素環化合物
US11713311B2 (en) Heterocyclic compound
EP4153583B1 (en) 1-((1h-pyrazol-4-yl)methyl)-3-(phenyl)-1,3-dihydro-2h-imidazol-2-one derivatives and related compounds as gpr139 antagonists for the treatment of depression
JP6675324B2 (ja) 複素環化合物
ES3006012T3 (en) Heterocyclic compound and use thereof
JP2025170366A (ja) 例えばうつ病の治療方法において使用するためのgpr139拮抗薬としての3-((1h-ピラゾール-4-イル)メチル)-6’-(フェニル)-2h-(1,2’-ビピリジン)-2-オン誘導体および関連化合物
JP2020517626A (ja) アセチルコリン受容体のモジュレーターとして有用な複素環化合物
US20240217957A1 (en) Heterocyclic compound and use thereof
TW202126623A (zh) 雜環化合物及其用途
EA051899B1 (ru) Производные 3-((1н-пиразол-4-ил)метил)-6'-(фенил)-2н-(1,2'-бипиридин)-2-она и связанные с ними соединения как антагонисты рецептора gpr139 для применения в способе лечения, например, депрессии
HK1261846A1 (en) Heterocyclic compound
HK1261846B (en) Heterocyclic compound